{
    "clinical_study": {
        "@rank": "149565", 
        "arm_group": [
            {
                "arm_group_label": "temozolomide", 
                "arm_group_type": "Active Comparator", 
                "description": "Four weeks after radiotherapy, patients will be received  6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)"
            }, 
            {
                "arm_group_label": "temozolomide +\u03b1-IFN", 
                "arm_group_type": "Experimental", 
                "description": "Four weeks after radiotherapy, patients will be received  6 cycle of temozolomide plus \u03b1-IFN \u03b1-IFN\uff1a3mIU (3million) Day1,3,5 of each 28 day TMZ\uff1a150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to help determine whether the addition of\n      Interferon-alpha(\u03b1-IFN),which were determined sensitized the activity of Temozolomide(TMZ)\n      in vivo and vitro,  when given along with temozolomide during the monthly cycles that follow\n      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with\n      newly diagnosed high-grade glioma."
        }, 
        "brief_title": "A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anaplastic Oligoastrocytoma", 
            "Anaplastic Astrocytoma", 
            "Glioblastoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Glioblastoma", 
                "Glioma", 
                "Oligodendroglioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is being conducted to help determine whether the addition of\n      Interferon-alpha(\u03b1-IFN),which were determined sensitized the activity of Temozolomide(TMZ)\n      in vivo and vitro,  when given along with temozolomide during the monthly cycles that follow\n      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with\n      newly diagnosed high-grade glioma. Four weeks after radiotherapy, newly diagnosed WHO III-IV\n      glioma patients will be randomised into two groups: TMZ group or TMZ+ \u03b1-IFN groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 years to 75 years\n\n          -  newly diagnosed WHO III-IV glioma after operation and radiotherapy\n\n          -  Karnofsky Performance Score \u2265 60\n\n          -  Adequate bone marrow, liver and renal function\n\n          -  Ability of subject to understand character and individual consequences    of  the\n             clinical trial\n\n          -  Written informed consent\n\n          -  anticipating survival  \u22652 months\n\n        Exclusion Criteria:\n\n          -  Refusal to participate the study\n\n          -  Known hypersensitivity or contraindication to temozolomide\n\n          -  Incompletely radiation\n\n          -  Pregnant or lactating females\n\n          -  Malignant tumor other than brain tumor\n\n          -  Contraindicated for MRI examination\n\n          -  Unable to comply with the follow-up studies of this trial\n\n          -  Purulent and chronic infected wounds\n\n          -  Uncontrolled psychotic disorders or epilepsy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765088", 
            "org_study_id": "CSNO2012001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "temozolomide", 
                    "temozolomide +\u03b1-IFN"
                ], 
                "description": "dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": "Temodar"
            }, 
            {
                "arm_group_label": "temozolomide +\u03b1-IFN", 
                "description": "3mIU (3million) D1\uff0c3\uff0c5", 
                "intervention_name": "\u03b1-IFN", 
                "intervention_type": "Drug", 
                "other_name": "INTRONA"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Temozolomide", 
                "Dacarbazine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "High-grade glioma", 
            "chemotherapy", 
            "Temozolomide", 
            "Interferon-alpha"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "contact": {
                "email": "chenzhp@sysucc.org.cn", 
                "last_name": "Zhong-ping Chen, MD,PhD", 
                "phone": "+86-20-87343310"
            }, 
            "contact_backup": {
                "email": "guochch@sysucc.org.cn", 
                "last_name": "Cheng-cheng Guo, MD,PhD", 
                "phone": "+86-20-87343656"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Zhong-ping Chen, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas", 
        "overall_contact": {
            "email": "chenzhp@sysucc.org.cn", 
            "last_name": "Zhong-ping CHEN, MD, PhD", 
            "phone": "+86-20-87343310"
        }, 
        "overall_contact_backup": {
            "email": "guochch@sysucc.org.cn", 
            "last_name": "Cheng-cheng GUO, MD, PhD", 
            "phone": "+86-20-87343309"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Over-all survival", 
            "safety_issue": "No", 
            "time_frame": "5-year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765088"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Zhongping Chen", 
            "investigator_title": "Professor and Chair, Department of Neurosurgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Quality of life", 
            "safety_issue": "No", 
            "time_frame": "5-year"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "West China Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chinese Academy of Medical Sciences", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}